Protagonist Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Protagonist Therapeutics (PTGX) Tops Q4 EPS by 2c, Revenues Miss
March 10, 2020 4:03 PM EDTProtagonist Therapeutics (NASDAQ: PTGX) reported Q4 EPS of ($0.63), $0.02 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $2.72 million versus the consensus estimate of $3.22 million.
"We are pleased to have made great progress in 2019, creating multiple opportunities to execute on our clinical... More
